Technical Name RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT
Project Operator National Taiwan University
Project Host 黃立民
Summary In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.
Scientific Breakthrough We constructed a modified RSV F protein, RSV-F005, to mimic the natural trimer conformation of the RSV F protein. The purified recombinant H-muad protein has been confirmed by TEM to form virus-like particles. The efficiency of H-muad to enhance mucosal immune responses was also fully evaluated in our mouse experiments with RSV candidate vaccine RSV-F005.
Industrial Applicability RSV vaccine is a brand new market segment. The treatment market of RSV is estimated to be reaching $2.3 billion in 2024.The FDA has been very conservative in reviewingapproving new vaccine adjuvants due to concerns about inappropriate side effects. Our candidate adjuvant H-muad is non-activerelatively safe nanoparticles. The global market for vaccine adjuvants is estimated to increase from $470
Technical Film
  • Contact
  • 黃任民
本網站使用您的Cookie於優化網站。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。